[Broker Focus] Western Securities maintains Giant Biotech's (02367) “buy” rating, indicating that the medical and aesthetic pipeline is expected to open a second curve after implementation

Jinwu Financial News | According to the Western Securities Research Report, Juzi Biotech (02367) achieved operating revenue of 3,524 billion yuan in 2023, +49.05%; among them, revenue from effective skincare products increased by +69.52% to 2,647 billion yuan. The volume of collagen bars, a star single product, increased. Currently, it accounts for about 30% of Kefumei's sales, becoming the core driving force contributing to Kefumei's revenue. Klein Star's single products have been sold more and more, and sales of Big Film King have been steadily increasing, and new film series are expected to become a new driving force for opening up the Klein anti-aging track. According to the bank, the company currently has four recombinant collagen plants

金吾財訊May 7 04:03 ET

Giant Biogene's Profit Up 47% in 2023

Giant Biogene Holding (HKG:2367) recorded a 47% rise in attributable profit for the year 2023 to 1.45 billion yuan, from 1 billion yuan in 2022, according to the company's annual report posted on the

MT NewswiresApr 30 06:27 ET

巨子生物：二零二三年年報

Futu NewsApr 29 09:36 ET · Announcements

[Broker Focus] Guolian Securities maintains Giazi Biotech (02367) “buy” rating, indicating that its high growth rate in 2024 is expected to continue

Jinwu Financial News | According to Guolian Securities Research Report, Juzi Biotech (02367) released its 2023 annual report: 2023 revenue of 3,524 billion yuan (+49.0% YoY), net profit to mother of 1,452 billion yuan (+44.9% YoY), and adjusted net profit of 1,469 billion yuan (YoY +39.0%). According to the bank, benefiting from the refined operation of multiple online platforms and the rapid release of Kefumei Collagen Stick Essence, online direct sales revenue increased 77.5% year-on-year in 2023/revenue share increased to 61.2%. Clekin will be in the channel adjustment period and product development period in 2023. Revenue

金吾財訊Apr 26 03:36 ET

With Giant Biogene Holding Co., Ltd. (HKG:2367) It Looks Like You'll Get What You Pay For

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 9x, you may consider Giant Biogene Holding Co., Ltd. (HKG:2367) as a stock to avoid entirely with its 29.

Simply Wall StApr 23 19:34 ET

Changes in Hong Kong stocks | Giant Biotech (02367) rose more than 5%, technological progress drives industry growth, institutions believe there is plenty of room for growth in the recombinant collagen industry

Giant Biotech (02367) rose by more than 5%. As of press time, it rose 5.51% to HK$45.95, with a turnover of HK$76.93 million.

Zhitong FinanceApr 16 23:09 ET